{"id":"NCT00106691","sponsor":"GTx","briefTitle":"Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-01","primaryCompletion":"2010-02","completion":"2010-02","firstPosted":"2005-03-30","resultsPosted":"2023-06-12","lastUpdate":"2023-06-12"},"enrollment":1589,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Preneoplastic Conditions","Prostatic Intraepithelial Neoplasia"],"interventions":[{"type":"DRUG","name":"Toremifene 20 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"20 mg Toremifene Citrate","type":"EXPERIMENTAL"},{"label":"Placebo","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine if toremifene citrate is effective and safe in the prevention of prostate cancer in men who have been diagnosed with high grade prostatic intraepithelial neoplasia (PIN).","primaryOutcome":{"measure":"Efficacy of Toremifene in the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN)","timeFrame":"The outcome measurement time is up to 36 months","effectByArm":[{"arm":"Placebo","deltaMin":54.9,"sd":36},{"arm":"Toremifene 20mg","deltaMin":59.5,"sd":36}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":14},"locations":{"siteCount":138,"countries":["United States","Argentina","Canada"]},"refs":{"pmids":["23295793"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":137,"n":802},"commonTop":["Hypertension","Arthralgia","Urinary tract infection","Upper respiratory tract infection","Prostatitis"]}}